A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies
The purpose of this follow-up study is to evaluate the frequency and persistence of specific viral mutations in response to treatment with ABT-333 (dasabuvir).
Procedure: Blood sample collection only
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||A Follow-up Study to Assess the Evolution and Persistence of Resistance to ABT-333 After Discontinuation of ABT-333 Therapy in HCV Genotype-1 Infected Subjects Who Participated in Phase 1, 2, or 3 ABT-333 Clinical Studies|
- Persistence of Resistance-Associated Variants and Phenotypic Resistance [ Time Frame: Baseline (day of study completion or early discontinuation from the prior ABT-333 clinical study), 48 weeks ] [ Designated as safety issue: No ]Participants in studies M10-351 (NCT00851890) and M10-380 (NCT00696904) were analyzed for persistence of resistance-associated variants by comparing post-treatment clonal sequence data with baseline and on-treatment sequence data from M10-351 and M10-380 studies to assess amino acid changes. Phenotypic resistance to ABT-333 was assessed by calculating the fold change in half maximal effective concentration (EC50) of post-treatment samples compared with the EC50 value for the corresponding baseline sample as determined for M10-351 and M10-380 studies. The number of participants with variants at resistance-associated amino acid positions and phenotypic resistance at post-treatment time points are presented. Variants are included if the absolute percent of total clones encoding the variant was at least 10% greater than at baseline in a post-treatment sample.
- Number of Participants With Serious Adverse Events Related to Study Procedures [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]Only serious adverse events that the investigator considered causally related to study procedures (i.e., venipuncture) were to be collected in this study. A serious adverse event was defined as any untoward medical occurrence in a clinical investigation subject that the investigator believed to be causally related to a study procedure and met at least 1 of the following criteria: death, life-threatening, hospitalization or prolongation of hospitalization, congenital anomaly, persistent or significant disability/incapacity, important medical event requiring medical or surgical intervention to prevent serious outcome, elective or spontaneous abortion.
|Study Start Date:||August 2008|
|Study Completion Date:||May 2010|
|Primary Completion Date:||May 2010 (Final data collection date for primary outcome measure)|
Hepatitis C virus (HCV)-infected participants who received ABT-333 at any dose level or matching placebo in a prior clinical study involving ABT−333.
Participants received no treatment in this follow-up study.
Procedure: Blood sample collection only
Approximately monthly collection of blood samples.Drug: ABT-333
Previous treatment in prior ABT-333 studies.
Other Name: dasabuvir
This Phase 2, multicenter study was conducted in HCV-infected participants who received ABT-333 at any dose level or matching placebo in a prior clinical study involving ABT−333. Hepatitis C virus (HCV)-infected participants who received ABT-333 at any dose level or matching placebo in Study M10-351 Substudy 2 (NCT00696904; ABT-333 dosing duration was 2 days) and Study M10-380 (NCT00851890; ABT-333 dosing duration was 28 days) were eligible.
After receiving at least 1 dose of ABT-333 or placebo, subjects were assessed for participation in this rollover study and asked to review the informed consent. The day of study completion or early discontinuation from the prior ABT-333 clinical study served as the baseline assessment. If it was found that a participant received placebo during the previous ABT-333 clinical study, the sites were instructed to discontinue the participant from this study.
This study included approximately monthly blood sample collection procedures for 48 weeks, and no treatment was provided during this time.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00726882
|United States, California|
|Site Reference ID/Investigator# 17665|
|Anaheim, California, United States, 92801|
|Site Reference ID/Investigator# 17367|
|Los Angeles, California, United States, 90036|
|Site Reference ID/Investigator# 17672|
|Los Angeles, California, United States, 90048|
|United States, Florida|
|Site Reference ID/Investigator# 10381|
|Orlando, Florida, United States, 32803|
|United States, Louisiana|
|Site Reference ID/Investigator# 17667|
|Baton Rouge, Louisiana, United States, 70808|
|United States, Texas|
|Site Reference ID/Investigator# 14461|
|San Antonio, Texas, United States, 78215|
|Site Reference ID/Investigator# 11141|
|Santurce, Puerto Rico, 00909|
|Study Director:||Daniel E Cohen, MD||AbbVie|